Microglia, the brain's primary immune cells, play a crucial role in responding to neural damage and are severely damaged during Alzheimer's progression. By stopping the Alzheimer's process at its starting point through enhancing mitochondrial immunity, we are halting all subsequent processes. The attached image tells a powerful story. The left panel shows compromised microglia in the 5xFAD model for Alzheimer's disease. The right panel, post-treatment with our VBIT formula, shows significantly more protected and active microglia. Our VBIT formula enhances mitochondrial immunity, halting neurodegeneration and protecting microglia from damage. This promising approach addresses the root cause and offers new hope for Alzheimer's patients. We are committed to advancing this research and ending Alzheimer's. Stay tuned for more updates. #ENDALZ
X-tosis
Biotechnology Research
Revolutionizing Alzheimer's treatment and stopping the progression of Alzheimer's at its core
About us
At X-Tosis, we are pioneering the future of Alzheimer’s treatment by targeting the disease at its core. Our innovative compound, VBIT, specifically inhibits the protein VDAC1, effectively halting mitochondrial dysfunction—a primary factor in Alzheimer’s progression. This groundbreaking approach aimed at stopping the progression of Alzheimer's and saving lives. Our mission is to stop Alzheimer's disease, not just slow it down.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2024
Updates
-
At X-Tosis, we envision a world where Alzheimer's no longer robs individuals of their memories and families of their loved ones. Our innovative compound, represents a groundbreaking advancement in the treatment of Alzheimer's by targeting mitochondrial dysfunction to halt neurodegeneration. Join us in this transformative journey. Together, we can make a difference and bring new hope to millions affected by Alzheimer's. #ENDALZ
-
Join us to make this day closer.
One day Alzhimer will be an old memory. #ENDALZ
-
🎉 Congrats to Eli Lilly and Company on FDA approval of donanemab for early Alzheimer's! A significant advancement to #ENDALZ
-
With the brightest we've got, working on a cure for Alzheimer's #EndAlz #BrainHealth #AlzheimersAwareness
-
-
We're #hiring a new Founder and Chief Executive Officer For a New Drug Development Company in United States. Apply today or share this post with your network.